149 related articles for article (PubMed ID: 26489554)
1. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor-Resistant Metastatic Breast Cancer].
Sakurai K; Fujisaki S; Suzuki S; Adachi K; Nagashima S; Masuo Y; Tomita R; Gonda K; Enomoto K; Amano S; Matsuo S; Umeda N
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1225-7. PubMed ID: 26489554
[TBL] [Abstract][Full Text] [Related]
2. [Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1286-8. PubMed ID: 25335719
[TBL] [Abstract][Full Text] [Related]
3. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Multiple Metastatic Breast Cancer Patients].
Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Hirano T; Enomoto K; Tomita R; Gonda K
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1233-1236. PubMed ID: 27760945
[TBL] [Abstract][Full Text] [Related]
4. [Indoleamine 2,3-Dioxygenase Activity during Fulvestrant Therapy for Aromatase Inhibitor Resistant Metastatic Breast Cancer].
Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
Gan To Kagaku Ryoho; 2017 Oct; 44(10):886-888. PubMed ID: 29066685
[TBL] [Abstract][Full Text] [Related]
5. [Indoleamine 2,3-dioxygenase activity in breast cancer patients with local recurrence or distant metastases].
Sakurai K; Fujisaki S; Suzuki S; Nagashima S; Maeda T; Tomita R; Hara Y; Hirano T; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1304-6. PubMed ID: 25335725
[TBL] [Abstract][Full Text] [Related]
6. [Indoleamine 2,3-Dioxygenase Activity during Letrozol Therapy for an Elderly Breast Cancer Patient].
Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T; Saga R; Makishima M
Gan To Kagaku Ryoho; 2017 Oct; 44(10):892-895. PubMed ID: 29066687
[TBL] [Abstract][Full Text] [Related]
7. [Indoleamine 2,3-Dioxygenase Activity in Intracystic Breast Tumors].
Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Enomoto K; Hirano T; Tomita R; Gonda K
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1295-1297. PubMed ID: 27760965
[TBL] [Abstract][Full Text] [Related]
8. [Indoleamine 2, 3-dioxygenase activity during neoadjuvant chemotherapy in patients with breast cancer].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1578-80. PubMed ID: 24393854
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Shibata M; Gonda K; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1776-8. PubMed ID: 23267883
[TBL] [Abstract][Full Text] [Related]
10. [Indoleamine 2, 3-dioxygenase activity for breast cancer patients with recurrence 5 or more years after surgery].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1590-2. PubMed ID: 24393858
[TBL] [Abstract][Full Text] [Related]
11. [Indoleamine 2,3-Dioxygenase Activity during I131-Radioisotope Therapy for Metastatic Thyroid Cancer].
Sakurai K; Fujisaki S; Adachi K; Suzuki S; Masuo Y; Nagashima S; Hara Y; Tomita R; Gonda K; Hirano T; Enomoto K
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1259-61. PubMed ID: 26489565
[TBL] [Abstract][Full Text] [Related]
12. [Indoleamine 2,3-Dioxygenase Activity during Long-Term Letrozole Therapy for Hormone Receptor-Positive Breast Cancer].
Suzuki Y; Sakurai K; Adachi K; Kubota H; Suzuki S; Takei S; Hara Y; Enomoto K; Hirano T; Makishima M
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1495-1497. PubMed ID: 30382056
[TBL] [Abstract][Full Text] [Related]
13. [Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Sakurai K; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2252-4. PubMed ID: 21224538
[TBL] [Abstract][Full Text] [Related]
14. [Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy].
Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S; Shiono M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2265-7. PubMed ID: 19106591
[TBL] [Abstract][Full Text] [Related]
15. [Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Shibata M; Gonda K; Tomita R; Suzuki S; Hara Y; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1791-3. PubMed ID: 23267888
[TBL] [Abstract][Full Text] [Related]
16. [Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer].
Sakurai K; Matsuo S; Enomoto K; Tani M; Kitajima A; Amano S
Gan To Kagaku Ryoho; 2009 Nov; 36(12):1991-3. PubMed ID: 20037301
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Perey L; Paridaens R; Hawle H; Zaman K; Nolé F; Wildiers H; Fiche M; Dietrich D; Clément P; Köberle D; Goldhirsch A; Thürlimann B
Ann Oncol; 2007 Jan; 18(1):64-69. PubMed ID: 17030543
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
[TBL] [Abstract][Full Text] [Related]
19. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Dodwell D; Vergote I
Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
[TBL] [Abstract][Full Text] [Related]
20. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
